메뉴 건너뛰기




Volumn 22, Issue 9 II, 2002, Pages

Dose conversion from recombinant human erythropoietin to darbepoetin alfa: Recommendations from clinical studies

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; SIALIC ACID; ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN;

EID: 0036367982     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.14.160s.33398     Document Type: Review
Times cited : (69)

References (14)
  • 1
    • 0034997401 scopus 로고    scopus 로고
    • Development and characterization of novel erythropoiesis stimulating protein (NESP)
    • (2001) Br J Cancer , vol.84 , Issue.SUPPL. 1 , pp. 3-10
    • Egrie, J.C.1    Browne, J.K.2
  • 11
    • 79960970663 scopus 로고    scopus 로고
    • Darbepoetin alfa administered every 1 or 2 weeks (with no loss of dose efficiency) alleviates anemia in patients with solid tumors
    • (2001) Blood , vol.98
    • Glaspy, J.1    Jadeja, J.2    Justice, G.3
  • 14
    • 0035155782 scopus 로고    scopus 로고
    • Novel erythropoiesis-stimulating protein, an erythropoietin analogue with an extended half-life and less frequent dosing
    • (2001) Formulary , vol.36 , pp. 19-25
    • Joy, M.S.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.